BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 116.48 USD 0.28%
Market Cap: $28B

Net Margin

-15.4%
Current
Declining
by 23.8%
vs 3-y average of 8.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-15.4%
=
Net Income
€-571.6m
/
Revenue
€3.2B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-15.4%
=
Net Income
$-571.6m
/
Revenue
€3.2B

Peer Comparison

Country Company Market Cap Net
Margin
DE
BioNTech SE
NASDAQ:BNTX
28B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 84% of companies in Germany
Percentile
16th
Based on 3 835 companies
16th percentile
-15.4%
Low
-222 027.4% — -2%
Typical Range
-2% — 6%
High
6% — 85 055.6%
Distribution Statistics
Germany
Min -222 027.4%
30th Percentile -2%
Median 2.2%
70th Percentile 6%
Max 85 055.6%

BioNTech SE
Glance View

BioNTech SE, founded in 2008 by the visionary duo Ugur Sahin and Özlem Türeci, has gradually emerged as a shining beacon in the world of biotechnology. Situated in Mainz, Germany, BioNTech carved its niche by focusing on the development of personalized therapies for cancer and other serious diseases. The company’s core competence lies in utilizing messenger RNA (mRNA) technology, which allows it to instruct the body to produce proteins that can stimulate an immune response. This technology became a game changer, not only in the cancer arena but also expanded its reach into infectious diseases, showcasing a broader horizon of possibilities. BioNTech’s ability to leverage its research expertise in mRNA placed it at the forefront of scientific innovation, demonstrating breathtaking adaptability and ingenuity. The company's business model thrives on strategic partnerships and collaborations, which bolster both its scientific output and financial standing. One of its most celebrated partnerships is with Pfizer, a collaboration that led to the development of the groundbreaking COVID-19 vaccine, Comirnaty. This collaboration thrust BioNTech onto the global stage, underscoring its capacity to swiftly respond to urgent health crises while generating substantial revenue. The success and distribution of the vaccine not only provided a significant boost to BioNTech’s financials but also validated its platform as powerful and versatile. By continually investing in research and development, both independently and through alliances, BioNTech aims to solidify its position as a leader in the evolving biotech landscape, paving the way for future therapies that could redefine medical treatments.

BNTX Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-15.4%
=
Net Income
€-571.6m
/
Revenue
€3.2B
What is BioNTech SE's current Net Margin?

The current Net Margin for BioNTech SE is -15.4%, which is below its 3-year median of 8.4%.

How has Net Margin changed over time?

Over the last 3 years, BioNTech SE’s Net Margin has decreased from 56.7% to -15.4%. During this period, it reached a low of -25.8% on Mar 31, 2025 and a high of 56.7% on Sep 30, 2022.

Back to Top